Research graph
References from Effect of loperamide on heart rhythm: Randomized, double-blind, controlled study in healthy adults. Local targets link to admitted publications; unresolved targets remain external evidence.
Loperamide (ADL 2–1294), an opioid antihyperalgesic agent with peripheral selectivity
1999 · External reference
Loperamide: a pharmacological review
2007 · External reference
Safety and efficacy of loperamide
10.1016/0002-9343(90)90269-j · 1990 · External reference
Abuse potential of loperamide
10.1038/clpt.1980.239 · 1980 · External reference
Electrocardiographic changes in loperamide toxicity: case report and review of literature
10.1111/jce.14129 · 2019 · External reference
Loperamide misuse to avoid opioid withdrawal and to achieve a euphoric effect: high doses and high risk
10.1080/15563650.2018.1510128 · 2019 · External reference
Epidemiologic trends in loperamide abuse and misuse
10.1016/j.annemergmed.2016.08.444 · 2017 · External reference
Loperamide misuse and abuse
10.1016/j.japh.2016.12.079 · 2017 · External reference
Loperamide cardiotoxicity: “A Brief Review”
10.1111/anec.12505 · 2018 · External reference
Loperamide-induced cardiac events: case reports and review
2021 · External reference
Cardiovascular toxicities associated with loperamide: analysis of the World Health Organization pharmacovigilance Database
10.1161/circulationaha.120.050587 · 2021 · External reference
Is there such a thing as a ‘lope’ dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports
10.1371/journal.pone.0204443 · 2018 · External reference
Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic
10.1007/s00210-016-1286-7 · 2016 · External reference
On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex
10.1111/j.1476-5381.2011.01415.x · 2011 · External reference
Potent inhibition of hERG channels by the over-the-counter antidiarrheal agent loperamide
10.1016/j.jacep.2016.07.008 · 2016 · External reference
Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity
10.1016/j.vascn.2017.08.006 · 2017 · External reference
The potential mechanisms behind loperamide-induced cardiac arrhythmias associated with human abuse and extreme overdose
10.3390/biom13091355 · 2023 · External reference
Dose proportionality study of loperamide following oral administration of loperamide oxide
10.1007/bf00265940 · 1992 · External reference
International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs; availability. Notice
2005 · External reference
Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review
10.1080/14740338.2018.1520837 · 2018 · External reference
The effect of moxifloxacin on QTc and implications for the design of thorough QT studies
10.1038/clpt.2008.33 · 2008 · External reference
QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs
10.1097/00045391-200311000-00013 · 2003 · External reference
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians
10.1185/03007995.2013.840568 · 2013 · External reference
QTc interval in the assessment of cardiac risk
10.1023/a:1016345412555 · 2002 · External reference
Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome-a European perspective
10.1111/j.1365-2036.2006.02937.x · 2006 · External reference
